NEW YORK (The Deal) -- Switzerland's Roche Holding on Sunday extended a summer of dealmaking with an agreement to buy InterMune (ITMN) for $8.3 billion to expand its treatments for respiratory ailments.
Roche, of Basel, would pay $74 per InterMune share, a 38% bonus to the target's Friday close. The price is also a 64% bump to the stock's close Aug. 12, the day before rumors of a strategic review at the target surfaced.
Acquisitive Roche is hoping to cash in on the pending U.S. approval of InterMune's pirfenidone treatment for idiopathic pulmonary fibrosis, or IPF. Patients with IPF gradually lose the ability to breath as fibers fill up their lungs.
"We look forward to welcoming InterMune employees into the Roche Group and to making a difference for patients with idiopathic pulmonary fibrosis, a devastating disease," said Roche CEO Severin Schwan in a statement.InterMune's new drug has already won approval in the European Union and Canada, where it is marketed under the name Esbriet. The IPF treatment has also already been acknowledged as a "breakthrough therapy" by the FDA and is expected to be cleared for use on Nov. 23, according to Roche.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV